Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny brain wave study aims to sharpen Alzheimer's drug testing

NCT ID NCT02899403

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study measured brain activity (EEG) in 6 healthy volunteers while they performed computer tasks that test attention and memory. The goal was to develop better ways to measure thinking skills that could be used in future Alzheimer's drug trials. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help create better ways to measure thinking and memory in healthy people, which might be used to test future Alzheimer's treatments.
What could go wrong
This was a very small pilot study (6 people) that was terminated early, so results are limited and may not apply to larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

May 2017

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Right-handed * In good health on the basis of the medical interview (medical history, symptoms), the physical examination and vital signs * Non smoker and with no history of drug or alcohol abuse * Without chronic treatment * With normal hearing and normal vision including color (with correction) * French speaker and able to understand the test instructions * Has provided written informed consent * Able to read and understand the Information Form and comply with the protocol instructions and restrictions Exclusion Criteria: * Cognitive impairment (MoCA \< 26) * Cognitive complaint (MacNair Scale \> 15) * History of brain disease (severe brain trauma, stroke, cerebral tumor…) or current cerebral disease * Major medical or surgical history * Current chronic disease * Vascular or metabolic risk factor * History or current mental disease or addiction (MINI) * Family history of young onset dementia * Family history of chronic or severe neurological or mental disease (first degree relatives) * In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason * Participates to another clinical trial or is still being within a washout period of a previous clinical trial * Already exposed to cognitive tests used in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Electroencephalographic variant pattern 1 (disorder)

Contacts and locations

Locations

  • Hôpital Cardiologique, CIC

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.